Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Methods A comprehensive search strategy was conducted to identify relevant studies focused on walking cadence and intensity for adults. Identified studies (n=38) included controlled (n=11), ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has proliferated, serving people looking for weight loss drugs at a fraction ...

Walking has never been hotter. Whether it’s walking clubs, fitness walkers advocating the health benefits on social media, or just the growing realization that taking a walk is a great way to ...

If you’re bored of your normal walking routine, this workout is a great way to mix things up. You’ll repeat a number of faster walking intervals, raising your heart rate and boosting your card ...

The primary outcome of this study was a change in maximum walking distance after 52 weeks, while a key secondary outcome was improvement in symptoms and quality of life. According to study results, ...

Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY ...

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass. There is a potential risk that ...